The Bootstrap Score™

Scientific quality is essential, but it is only one part of commercialization readiness. The Bootstrap Score™ is a practical framework for asking a more useful question: how much of the commercial risk has been reduced around the science?

The framework evaluates an opportunity across the areas that most often determine whether promising research can become a fundable, licensable, or buildable product. The point is not to create a perfect numerical prediction. It is to expose the weak links that can consume time, capital, and founder equity later.

• Unmet need: Is the problem important enough that someone will change behavior, pay, license, adopt, or reimburse a solution?
• Product definition: Is there a clear product concept, intended user, use setting, and target customer?
• Evidence: Does the existing data answer commercially relevant questions, not only scientific ones?
• Intellectual property: Is there a protectable position, freedom-to-operate strategy, or other defensibility?
• Regulatory path: Is the likely FDA pathway and evidence burden understood at a useful level?
• Reimbursement and economics: Is there a plausible route to payment and an attractive value proposition?
• Team and execution: Are the capabilities needed for the next stage available internally or through advisors and partners?
• Funding fit: Is the next source of capital matched to the next value-creating milestone?
  

Score each category from 1 to 5. A low score does not mean the science is weak; it means the commercialization plan contains unanswered questions. A high score should reflect evidence and decisions, not optimism.

The most useful result is usually not the total score. It is the pattern. A project can have extraordinary science and still be fragile because regulatory, reimbursement, customer, or IP assumptions have not been tested.

• 1 = largely unknown or untested
• 3 = working hypothesis with some supporting evidence
• 5 = clearly defined and supported by credible evidence
  

Prioritize the lowest-scoring categories that could invalidate the business model or materially change the development plan. In many cases, one focused customer-discovery effort, regulatory assessment, IP review, or reimbursement analysis can prevent months of unfocused work.

BYB Takeaway

The purpose of the Bootstrap Score™ is not to tell you whether to start a company. It is to identify what must become true before the company deserves more capital, more founder time, or more dilution.

Want to pressure-test your commercialization readiness? Visit Bootstrap Your Biotech for commercialization resources and advisory support.